Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (CRXT) is a specialty pharmaceutical company that completed its business combination with Blue Water Acquisition Corp., a blank-check vehicle sponsored by Blue Water Capital, bringing it to the public markets in early 2021. The company, focused on men's health therapeutics including its oral testosterone replacement product, filed an 8-K current report with the SEC on May 3, 2021, disclosing a reportable corporate event in the period following its SPAC merger. Operating in the biopharma and specialty healthcare sector, CRXT traded on Nasdaq as a post-combination company. Investors and analysts tracking SPAC-originated healthcare names can access the full filing history, deal timeline, and sponsor details for CRXT by signing up for complete data on SpacDesk.